GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Search
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
Combating complex diseases with data
How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
Winners of the 2020 European PRRS Research Award
Winners of the 2020 European PRRS Research Award announced Three winner awarded 25,000 euro each for their research.
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
VAXXITEK HVT + IBD
To prevent mortality and to reduce clinical signs and lesions of infectious bursal disease. To reduce mortality, clinical signs and lesions of Marek’s disease.
LongRange
Longrange® is effective in the control of most internal and external parasites of cattle: gastrointestinal roundworms, lungworms, grubs, mites.
Winners of 2020 BVDzero Case Awards
Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.
Stroke Prevention in AF
Stroke Prevention in AF
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Employees empower small dairy producers
Boehringer Ingelheim social intrapreneurship helps farmers improve animal welfare and the well-being of rural communities in Southern India.
Ileitis prevention vaccination Lawsonia intracellularis pig
Cause, impact and prevention: Learn the essentials about Ileitis
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
university-of-medical-excellence-harvard
A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
global-top-employer
For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
Earthquakes Türkiye & Syria
Support for those impacted by Türkiye & Syria earthquakes
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Boehringer biopharmaceuticals China receives approval supply EU and US
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market